Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy

NCT00499369 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

72

Enrollment

NIH

Sponsor class

Stopped Due to inadequate accrual, study was terminated and limited outcome data was reported.

Conditions

Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer

Interventions

DRUG: irinotecan hydrochloride
DRUG: leucovorin calcium
DRUG: fluorouracil
BIOLOGICAL: cetuximab
BIOLOGICAL: bevacizumab

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]